Lauren A Apodaca1, Al Anoud D Baddour1, Camilo Garcia1, Leila Alikhani1, Erich Giedzinski1, Ning Ru1, Anshu Agrawal2, Munjal M Acharya3, Janet E Baulch4. 1. Department of Radiation Oncology, University of California Irvine, Irvine, CA, 92697, USA. 2. Department of Medicine, University of California Irvine, Irvine, CA, 92697, USA. 3. Department of Radiation Oncology, University of California Irvine, Irvine, CA, 92697, USA. macharya@uci.edu. 4. Department of Radiation Oncology, University of California Irvine, Irvine, CA, 92697, USA. jbaulch@uci.edu.
Abstract
BACKGROUND: Regenerative therapies to mitigate Alzheimer's disease (AD) neuropathology have shown very limited success. In the recent era, extracellular vesicles (EVs) derived from multipotent and pluripotent stem cells have shown considerable promise for the treatment of dementia and many neurodegenerative conditions. METHODS: Using the 5xFAD accelerated transgenic mouse model of AD, we now show the regenerative potential of human neural stem cell (hNSC)-derived EVs on the neurocognitive and neuropathologic hallmarks in the AD brain. Two- or 6-month-old 5xFAD mice received single or two intra-venous (retro-orbital vein, RO) injections of hNSC-derived EVs, respectively. RESULTS: RO treatment using hNSC-derived EVs restored fear extinction memory consolidation and reduced anxiety-related behaviors 4-6 weeks post-injection. EV treatment also significantly reduced dense core amyloid-beta plaque accumulation and microglial activation in both age groups. These results correlated with partial restoration of homeostatic levels of circulating pro-inflammatory cytokines in the AD mice. Importantly, EV treatment protected against synaptic loss in the AD brain that paralleled improved cognition. MiRNA analysis of the EV cargo revealed promising candidates targeting neuroinflammation and synaptic function. CONCLUSIONS: Collectively, these data demonstrate the neuroprotective effects of systemic administration of stem cell-derived EVs for remediation of behavioral and molecular AD neuropathologies.
BACKGROUND: Regenerative therapies to mitigate Alzheimer's disease (AD) neuropathology have shown very limited success. In the recent era, extracellular vesicles (EVs) derived from multipotent and pluripotent stem cells have shown considerable promise for the treatment of dementia and many neurodegenerative conditions. METHODS: Using the 5xFAD accelerated transgenicmouse model of AD, we now show the regenerative potential of human neural stem cell (hNSC)-derived EVs on the neurocognitive and neuropathologic hallmarks in the AD brain. Two- or 6-month-old 5xFAD mice received single or two intra-venous (retro-orbital vein, RO) injections of hNSC-derived EVs, respectively. RESULTS:RO treatment using hNSC-derived EVs restored fear extinction memory consolidation and reduced anxiety-related behaviors 4-6 weeks post-injection. EV treatment also significantly reduced dense core amyloid-beta plaque accumulation and microglial activation in both age groups. These results correlated with partial restoration of homeostatic levels of circulating pro-inflammatory cytokines in the ADmice. Importantly, EV treatment protected against synaptic loss in the AD brain that paralleled improved cognition. MiRNA analysis of the EV cargo revealed promising candidates targeting neuroinflammation and synaptic function. CONCLUSIONS: Collectively, these data demonstrate the neuroprotective effects of systemic administration of stem cell-derived EVs for remediation of behavioral and molecular AD neuropathologies.
Authors: Munjal M Acharya; Lori-Ann Christie; Mary L Lan; Erich Giedzinski; John R Fike; Susanna Rosi; Charles L Limoli Journal: Cancer Res Date: 2011-07-14 Impact factor: 12.701
Authors: Munjal M Acharya; Vahan Martirosian; Nicole N Chmielewski; Nevine Hanna; Katherine K Tran; Alicia C Liao; Lori-Ann Christie; Vipan K Parihar; Charles L Limoli Journal: Cancer Res Date: 2015-02-15 Impact factor: 12.701
Authors: Dieter Edbauer; Joel R Neilson; Kelly A Foster; Chi-Fong Wang; Daniel P Seeburg; Matthew N Batterton; Tomoko Tada; Bridget M Dolan; Phillip A Sharp; Morgan Sheng Journal: Neuron Date: 2010-02-11 Impact factor: 17.173
Authors: Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2012-05 Impact factor: 3.685
Authors: Sudhanshu Agrawal; Janet E Baulch; Shreya Madan; Seher Salah; Samantha N Cheeks; Robert P Krattli; Veedamali S Subramanian; Munjal M Acharya; Anshu Agrawal Journal: Cell Mol Life Sci Date: 2022-06-01 Impact factor: 9.207